At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 98 target
Drug / intervention
BL-M07D1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06114511Phase 2RecruitingMonitorUpdated 10mo ago · Completion was 3mo agoSlow Enrollment
Monitor
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2 Mutated, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating BL-M07D1 for Non-small Cell Lung Cancer. Currently recruiting, targeting 98 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2RecruitingOverdue
202420252026
First PostedNov 2023
Enrollment StartApr 2024
Primary CompletionApr 2026
TodayJul 2026
First PostedNov 2, 2023
Enrollment StartApr 24, 2024
Primary CompletionApr 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 2.7 years ago
Interventions
BL-M07D1drug
Administration by intravenous infusion